Fig 1: Iron-loaded iPS-RPE accumulate lysosomes with impaired enzyme activity. (A) Western blot analysis of human iPS-RPE loaded with 50 μM FeSO4 for 6 and 9 weeks. AzureRed total protein stain served as a loading control. Each lane represents one experimental replicate. (B) Representative confocal images of human iPS-RPE cells loaded with LysoTracker (red) to detect lysosomes and DQ-BSA (green) to detect lysosomal proteolysis. Nuclei are labeled with DAPI (blue). Scale bars: 10 μm. (C) Quantification of LysoTracker-positive puncta per cell. (D) Quantification of DQ-BSA-positive puncta per cell. (E) Measurement of lysosomal pH using LysoSensor Yellow/Blue, with higher values of the 340/380 ratio correlating to increased pH. (F-J) Enzyme activity assays for cathepsin D (F), cathepsin B (G), glucosylceramidase (GCase) (H), acid sphingomyelinase (aSMase) (I) and lysosomal acid lipase (LAL) (J). Cells were incubated with 0, 50 or 100 μM FeSO4 for 6 weeks in B-J. Values in graphs represent the mean±s.e.m. RFU, relative fluorescence units. ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 (two-tailed unpaired Student's t-test).
Fig 2: Lysosomal function is not affected by WT or mutant 14-3-3θ expression in isyn cells. a. Representative blots and quantification of LC3-I and LC3-II levels after CQ treatment in doxy-induced isyn cells without and with WT or mutant 14-3-3θ expression. n = three independent rounds. * p < 0.05 (Tukey’s multiple comparison test). n.s. non-significant. b. Representative images and quantification of DQ-BSA activity in doxy-induced isyn cells without and with WT or mutant 14-3-3θ expression. n = 10 individual cells per condition per round with three independent rounds (total 30 cells imaged per condition). n.s. (One-way ANOVA). Scale bar 20 μm. c. Representative images and quantification of lysosomal lipase A (LAL) activity in doxy-induced isyn cells without and with WT or mutant 14-3-3θ expression. n = 10 individual cells per condition per round with three independent rounds (total 30 cells imaged per condition). n.s. (One-way ANOVA). Scale bar 20 μm. Error bars represent standard error.
Fig 3: The S232D mutation increases αsyn inclusion formation, while the S232A mutation protects against αsyn inclusion formation upon PFF treatment in neurons. a. Representative images of Cre control, Cre+/− S232D+/−, and Cre+/− S232D+/+ hippocampal neurons treated with monomeric or fibrillary αsyn at DIV 5 and then fixed and stained at 7, 10, or 14 days after treatment for insoluble, pS129 αsyn. Scale bar 100 μm. b. Quantification of area positive for pS129-αsyn immunostaining in hippocampal cultures from Cre control, Cre+/− S232D+/−, and Cre+/− S232D+/+ treated with αsyn PFFs. n = six independent rounds with 1–2 replicates per round. *p < 0.05, ****p < 0.0001 (Tukey’s multiple comparison test). c. Quantification of DQ-BSA activity in Cre control and Cre+/− S232D+/+ primary hippocampal neurons at DIV 8. n.s. (Student’s t-test). d. Quantification of LAL activity in Cre control and Cre+/− S232D+/+ primary hippocampal neurons at DIV 8. n.s. (Student’s t-test). e. Representative images of Cre control and Cre+/− S232A+/+ hippocampal neurons treated with fibrillary αsyn at DIV5 and then fixed and stained for insoluble, pS129 αsyn at 7, 10, or 14 days after treatment. Scale bar 100 μm. f. Quantification of area positive for pS129-αsyn immunostaining in hippocampal cultures from Cre control and Cre+/− S232A+/+ treated with αsyn PFFs. n = three independent rounds with two replicates per round. *p < 0.05, ****p < 0.0001 (Tukey’s multiple comparison test). Error bars represent standard error.
Fig 4: Increased Npc1, Npc2, and Nceh1 expression in pristane-treated mice. Mice were treated with pristane (Pris) or mineral oil (MO) and 14-d later, gene expression was evaluated in peritoneal CD11b+Ly6ChiCD138− and CD11b+Ly6ChiCD138− Mϕ by RNA-Seq (A-I) or in total PECs by qPCR (J). (A-I), Relative expression of genes encoding proteins involved in the regulation of intracellular lipid homeostasis (RNA-Seq): Npc1, Npc2, Nceh1, Ldlr, Cd36, Ptafr, Lipa, Acat1, and Hmgr. (J), Expression of Npc1, Npc2, and Nceh1 in PECs from pristane and MO treated mice (qPCR). Fpkm, fragment per kilobase million. *, P < 0.05; **, P < 0.01; *** P < 0.001, ns, not significant (Student t-test).
Fig 5: Effect of U18666A on lysosomal enzymes. (A), B6 mice were treated with pristane or mineral oil (MO) and lysosomal acid lipase (LAL) enzyme activity was measured at day-14 in CD11b+CD138+Ly6G− Mϕ, CD11b+CD138−Ly6G− Mϕ, and CD11b+CD138−Ly6G+ neutrophils. (B), B6 mice were treated with pristane alone (-) or pristane + U18666A. Lysosomal acid lipase (LAL) enzyme activity was measured at day-14 in CD11b+CD138+Ly6G− Mϕ, CD11b+CD138−Ly6G− Mϕ, and CD11b+CD138−Ly6G+ neutrophils. (C-D), mRNA expression (qPCR) at day-14 in total PECs from mice treated with pristane or MO or pristane+U18666A. (C), lysosomal acid lipase (Lipa) expression. (D), cathepsin S (Ctss), cathepsin D (Ctsd), cathepsin L (Ctsl) and cathepsin K (Ctsk) expression. (E), expression of Ctss, Ctsd, Ctsl, and Ctsk in total PECs from B6 mice treated with pristane alone (Pris) or pristane + U18666A. F, CTSK enzyme activity 14-d after pristane or MO treatment in peritoneal exudate cell (PEC) subsets: L6G+ neutrophils (left), Ly6G−CD11b+CD138+ Mϕ (middle), and Ly6G−CD11b+CD138− Mϕ (right). *, P < 0.05; **, P < 0.01; *** P < 0.001; **** P < 0.0001; ns, not significant (Student t-test).
Supplier Page from Abcam for LysoLive™ Lysosomal Acid Lipase Assay Kit